Cor Vasa 2023, 65(5):779-782 | DOI: 10.33678/cor.2023.009

Posterior reversible encephalopathy syndrome caused by contrast media after percutaneous coronary intervention

İbrahim Saraça, Gökhan Tonkazb, Faruk Aydinyilmaza, Emrah Aksakala
a Department of Cardiology, University of Health Sciences, Erzurum Education and Research Hospital, Erzurum, Turkey
b Department of Radiology, University of Health Sciences, Erzurum Education and Research Hospital, Erzurum, Turkey

Contrast media use is an integral part of invasive procedures, mainly radiodiagnostic procedures, performed for diagnosis and treatment in the cardiac catheterization laboratory. There are many complications related to contrast agents after percutaneous coronary intervention (PCI). Contrast-induced neurotoxicity is a rarely reported complication that may result with encephalopathy. In this report, posterior reversible encephalopathy syndrome (PRES), a rare consequence of neurotoxicity of iodinated contrast agents with acute onset, reversible with early diagnosis and treatment, and diagnosed by neurologic examination radiological imaging methods, will be mentioned.

Keywords: Contrast agent, Encephalopathy, Percutaneous coronary intervention

Received: December 2, 2022; Revised: January 4, 2023; Accepted: January 22, 2023; Published: October 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Saraç İ, Tonkaz G, Aydinyilmaz F, Aksakal E. Posterior reversible encephalopathy syndrome caused by contrast media after percutaneous coronary intervention. Cor Vasa. 2023;65(5):779-782. doi: 10.33678/cor.2023.009.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rashid H, Brown J, Nix E, Fisher Covin A. Contrast-Induced encephalopathy following diagnostic coronary angiography. Clin Case Rep 2022;10:e05624. Go to original source... Go to PubMed...
    2. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007;28:1320-1327. Go to original source... Go to PubMed...
    3. Fischer M, Schmutzhard E. Posterior reversible encephalopathy syndrome. J Neurol 2017;264:1608-1616. Go to original source... Go to PubMed...
    4. Legriel S, Schraub O, Azoulay E, et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One 2012;7:e44534. Go to original source... Go to PubMed...
    5. Leong S, Fanning NF. Persistent neurological deficit from iodinated contrast encephalopathy following intracranial aneurysm coiling. A case report and review of the literature. Interv Neuroradiol 2012;18:33-41. Go to original source... Go to PubMed...
    6. Kocabay G, Karabay CY. Iopromide-induced encephalopathy following coronary angioplasty. Perfusion 2011;26:67-70. Go to original source... Go to PubMed...
    7. Torvik A, Walday P. Neurotoxicity of water-soluble contrast media. Acta Radiol Suppl 1995;399:221-229. Go to original source... Go to PubMed...
    8. Ulas T, Buyukhatipoglu H, Dal MS, et al. Urotensin-II and endothelin-I levels after contrast media administration in patients undergoing percutaneous coronary interventions. J Res Med Sci 2013;18:205-209.
    9. Granata G, Greco A, Iannella G, et al. Posterior reversible encephalopathy syndrome - Insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2015;14:830-836. Go to original source... Go to PubMed...
    10. Liu MR, Jiang H, Li XL, Yang P. Case Report and Literature Review on Low-Osmolar, Non-Ionic Iodine-Based Contrast-Induced Encephalopathy. Clin Interv Aging 2020;15:2277-2289. Go to original source... Go to PubMed...
    11. Barbieri L, Verdoia M, Marino P, et al.; Novara Atherosclerosis Study G. Contrast volume to creatinine clearance ratio for the prediction of contrast-induced nephropathy in patients undergoing coronary angiography or percutaneous intervention. Eur J Prev Cardiol 2016;23:931-937. Go to original source... Go to PubMed...
    12. Muruve DA, Steinman TI. Contrast-induced encephalopathy and seizures in a patient with chronic renal insufficiency. Clin Nephrol 1996;45:406-409.
    13. Zhao W, Zhang J, Song Y, et al. Irreversible fatal contrast-induced encephalopathy: a case report. BMC Neurol 2019;19:46. Go to original source... Go to PubMed...
    14. Parasher A, Jhamb R. Posterior reversible encephalopathy syndrome (PRES): presentation, diagnosis and treatment. Postgrad Med J 2020;96:623-628. Go to original source... Go to PubMed...
    15. Cui HW, Lei RY, Zhang BA. Clinical Features and Risk Factors of Mortality in Patients with Posterior Reversible Encephalopathy Syndrome. Behav Neurol 2022;2022:9401661. Go to original source... Go to PubMed...
    16. Liu X, Liu H, Wang L, et al. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. PLoS One 2022;17:e0263131. Go to original source... Go to PubMed...
    17. Casale M, Mezzetti M, De Fazio MG, et al. Usefulness of Sacubitril/Valsartan in reduction of atrial fibrillation burden in a patient with ICD delivering inappropriate therapies. A new possibility? Cor Vasa 2020;62:336-339. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes